We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Clinical track: Prostate
Poster
Clinical
00:00 - 00:00
Long-term results of high-precision salvage radiation therapy after radical prostatectomy
PO-1149
00:00 - 00:00
Isolated bone metastases in prostate patients: preliminary analysis from two phase I trials on SRS
PO-1153
00:00 - 00:00
Is the dose-distribution in bladder really unimportant for GU toxicity in prostate cancer patients?
PO-1151
00:00 - 00:00
POST HIFU SALVAGE RADIOTHERAPY IN LOCALLY RELAPSED PROSTATE CARCINOMA: A MONO-INSTITUTIONAL ANALYSIS
PO-1162
00:00 - 00:00
68Ga-PSMA PET-GUIDED METASTASES DIRECTED STEREOTACTIC BODY RADIOTHERAPY IN PROSTATIC CANCER PATIENTS
PO-1163
00:00 - 00:00
Long-term outcomes of radiotherapy regimen of 72 Gy in 30 fractions for prostate cancer
PO-1164
00:00 - 00:00
The Impact of Undetectable PSA After Salvage Radiotherapy for Prostate Cancer
PO-1155
00:00 - 00:00
Assessing the potential gains of a decision support system for primary treatment of prostate cancer
PO-1154
00:00 - 00:00
THE ROLE OF MAGNETIC RESONANCE IMAGING IN PROSTATE CANCER
PO-1156
00:00 - 00:00
A pilot dual-platform transcriptomic analysis of diagnostic prostate biopsies & radical RT response
PO-1160
00:00 - 00:00
Postoperative Prostate Cancer treated with High-dose Radiotherapy.
PO-1152
00:00 - 00:00
Mobile app of individualized Patient Decision Aid for prostate cancer based on predictive models.
PO-1158
00:00 - 00:00
Short-term results of coverage probability radiotherapy of MRI-staged prostate cancer
PO-1157
00:00 - 00:00
Toxicity Profile in Postoperative Radiotherapy for Prostate Cancer with Moderate Hypofractionation
PO-1159
00:00 - 00:00
Biological target volume delineated and 3D UI guided hypofractional radiotherapy for prostate cancer
PO-1150
00:00 - 00:00
The first study in outcomes and toxicity of definite VMAT for prostate cancer in Southeast Asia
PO-1161
00:00 - 00:00
The 100 most cited articles in prostate cancer brachytherapy: A bibliometric study
PO-1190
00:00 - 00:00
SIB-VMAT for DIL in prostate cancer: the preliminary result in acute toxicity and quality of life
PO-1191
00:00 - 00:00
Radiotherapy in high risk prostate cancer: Whole pelvic radiotherapy vs prostate only radiotherapy
PO-1168
00:00 - 00:00
Influence of localisation of PSMA-positive oligo-metastases on efficacy of metastasis-directed EBRT
PO-1169
00:00 - 00:00
Long-Term testosterone levels and its influence in treatment outcomes in prostate cancer patients
PO-1170
00:00 - 00:00
Elective Pelvic Nodes Irradiation in Patients with Prostate Cancer (PRO-EPI Study)
PO-1192
00:00 - 00:00
18F-CHOLINE PET/68Ga-PSMA PET SBRT IN OLIGORECURRENT PROSTATE CANCER: COMPARATIVE ANALYSIS
PO-1193
00:00 - 00:00
MR-based adaptive IGRT of prostate cancer: feasibility, plan adaptation and acute toxicity
PO-1194
00:00 - 00:00
Impact of Adjuvant Radiotherapy in node positive prostate cancer patients
PO-1195
00:00 - 00:00
long term results with moderately hypofractionated RT in high-risk localized prostate cancer.
PO-1196
00:00 - 00:00
Short-term high precision RT for early PCa with SIB to the DIL: QoL assessment (AIRC IG 13218)
PO-1197
00:00 - 00:00
Comparison between built custom linked seeds and loose seeds in prostate brachytherapy
PO-1198
00:00 - 00:00
Low- and Intermediate-Risk Prostate Cancer. Stereotactic Body Radiation Therapy. Our experience.
PO-1171
00:00 - 00:00
Rectal toxicity prostate cancer treated with Brachytherapy: a radiomics-machine learning based NTCP
PO-1199
00:00 - 00:00
Multimodality treatment for M1a prostate cancer: toxicity and early oncological results.
PO-1200
00:00 - 00:00
Oligorecurrent prostate cancer treated with metastasis-directed therapy: oncological outcomes
PO-1201
00:00 - 00:00
Toxicity and outcomes of postoperative hypofractionated Helical Tomotherapy for prostate cancer
PO-1165
00:00 - 00:00
CHHiPvsPROFIT for Localized Prostate Cancer:A Retrospective Dosimetric Comparison of Organs at Risk.
PO-1202
00:00 - 00:00
Urethral sparing prostate SABR with integrated boost: novel by-stander effect of hydrogel spacer
PO-1203
00:00 - 00:00
CLINICAL OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED HDR BT
PO-1204
00:00 - 00:00
dose effects due to interfractional variability for hypofractionated radiotherapy of prostate cancer
PO-1172
00:00 - 00:00
Long term results of IG-IMRT in high risk prostate cancer patients: a monoinstitutional experience
PO-1173
00:00 - 00:00
IMRT versus 3D-CRT in the treatment of prostate cancer: comparison of outcomes and toxicity.
PO-1166
00:00 - 00:00
Results of a multinational clinical audit for prostate cancer radiotherapy: the IROCA project
PO-1174
00:00 - 00:00
SBRT for localised prostate cancer – Nordic results with mFU of 5.3 years
PO-1175
00:00 - 00:00
Ultra-hypofractionated SBRT for localized prostate cancer: single institution experience
PO-1176
00:00 - 00:00
Treatment-related toxicity using prostate only vs prostate and pelvic lymph node radiation therapy.
PO-1177
00:00 - 00:00
Identifying skeletal-related events for prostate cancer in routinely collected hospital data.
PO-1178
00:00 - 00:00
Patient-reported outcomes following a high-dose rate brachytherapy boost for prostate cancer.
PO-1179
00:00 - 00:00
Patterns of failure after stereotactic ablative radiotherapy for abdomino-pelvic nodal disease
PO-1180
00:00 - 00:00
Metastasis-Directed Therapy influence in clinical outcomes of oligorrecurrent prostate cancer
PO-1181
00:00 - 00:00
PSMA-PET is superior to choline-PET based SABR for ADT deferral in oligometastatic prostate cancer
PO-1182
00:00 - 00:00
Do we need sigma constraints in era of intensity-modulated radiation therapy for prostate cancer?
PO-1183
00:00 - 00:00
THE SIGNIFICANCE OF NOMOGRAMS FOR PREDICTING NODE METASTASIS IN 68Ga-PSMA-PET/CT IN PROSTATE CANCER
PO-1184
00:00 - 00:00
Results of prostate cancer patients treated by integrated boost to dominant intraprostatic lesion
PO-1185
00:00 - 00:00
Impact of a low FODMAP diet on rectal gas and rectal volume during radiotherapy of prostate cancer
PO-1186
00:00 - 00:00
A gene signature-based model to predict BCR-free survival after radical prostatectomy
PO-1187
00:00 - 00:00
Optimal radiotherapy strategy as risk-group in non-metastatic prostate cancer patients (KROG 18-15)
PO-1188
00:00 - 00:00
Salvage therapies for PSMA PET-positive nodal recurrent prostate cancer
PO-1167
00:00 - 00:00
VMAT SBRT for localized prostate cancer: 5-year update on toxicity and survival
PO-1189